Nielsen linus cam4

Please set your browser to accept cookies to continue.

This cookie stores just a session ID; no other information is captured.

For 157 primary invasive breast carcinomas from patients who all developed metastatic disease, m RNA expression signatures were assessed using microarray analysis.The patient characteristics and metastasis patterns are described in Table ].79.4 % of the patients with Luminal A, 72.5 % of Luminal B, 78.6 % HER2-like and 87.5 % of basal-type tumours received adjuvant therapy.None of the patients received trastuzumab as adjuvant therapy; a subgroup of patients (Bone was the most frequent site of distant metastasis (71.5 %) followed by liver (51.7 %) and lung (34.4 %).Hereafter they have validated these gene expression signatures in several cohorts of primary breast tumours with known metastatic disease.

We have recently described the metastatic behaviour (organ-specific metastasis)-related immunophenotypic findings of the primary tumours in a retrospective study including 263 primary breast tumours with known metastatic disease [].Accepting the NEJM cookie is necessary to use the website.Metastatic cancer remains the leading cause of death for patients with breast cancer.To understand the mechanisms underlying the development of distant metastases to specific sites is therefore important and of potential clinical value.From 157 primary breast tumours of the patients with known metastatic disease, gene expression profiling data were generated and correlated to metastatic behaviour including site-specific metastasis, metastasis pattern and survival outcomes.Weitere Informationen zu unseren Cookies und dazu, wie du die Kontrolle darüber behältst, findest du hier: Cookie-Richtlinie.